Benzinga | Aug 3, 2021 11:40AM EDT

Needham Maintains Strong Buy on Esperion Therapeutics, Lowers Price Target to $114

Needham analyst Chad Messer maintains Esperion Therapeutics (NASDAQ:ESPR) with a Strong Buy and lowers the price target from $134 to $114.